{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:22:55Z","timestamp":1779315775524,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rmed.2025.108168","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:07:57Z","timestamp":1747739277000},"page":"108168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"244","author":[{"given":"Cong","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunfan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanpeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108168_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(18)30407-9","article-title":"The global burden of lower respiratory infections: making progress, but we need to do better","volume":"18","author":"Murdoch","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib3","first-page":"139","article-title":"Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study","volume":"12","author":"Marrie","year":"2005","journal-title":"Cancer Res. J."},{"key":"10.1016\/j.rmed.2025.108168_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12879-015-1162-y","article-title":"Rates of pneumonia among children and adults with chronic medical conditions in Germany","volume":"15","author":"Pelton","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12877-018-0787-2","article-title":"The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States","volume":"18","author":"Brown","year":"2018","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.rmed.2025.108168_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/cid\/cis242","article-title":"Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia","volume":"54","author":"Avdic","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/cid\/ciw780","article-title":"What is the more effective antibiotic stewardship intervention: preprescription authorization or postprescription review with feedback?","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2025.108168_bib8","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijantimicag.2010.03.010","article-title":"Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials","volume":"36","author":"An","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.rmed.2025.108168_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.rmed.2025.108168_bib12","first-page":"687","article-title":"Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials","volume":"125","author":"Zhang","year":"2012","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.rmed.2025.108168_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijantimicag.2019.05.023","article-title":"Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis","volume":"54","author":"Eljaaly","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.rmed.2025.108168_bib15","first-page":"501","article-title":"Efficacy of ceftriaxone 1 g daily versus 2 g daily for the treatment of community-acquired pneumonia: a systematic review with meta-analysis, expert rev. Anti","volume":"17","author":"Telles","year":"2019","journal-title":"Infect. Ther."},{"key":"10.1016\/j.rmed.2025.108168_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2025.108168_bib17","author":"Higgins","year":"2011","journal-title":"Cochrane Handbook for Systematic Review of InterventionsVersion 5.1.0"},{"key":"10.1016\/j.rmed.2025.108168_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.rmed.2025.108168_bib19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.rmed.2025.108168_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2025.108168_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.rmed.2025.108168_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2025.108168_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2025.108168_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2288-12-150","article-title":"Adjustment for reporting bias in network meta-analysis of antidepressant trials","volume":"12","author":"Trinquart","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.rmed.2025.108168_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.11150\/kansenshogakuzasshi1970.58.525","article-title":"[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]","volume":"58","author":"Kobayashi","year":"1984","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.rmed.2025.108168_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.11150\/kansenshogakuzasshi1970.58.1083","article-title":"[Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method]","volume":"58","author":"Miki","year":"1984","journal-title":"Kansenshogaku Zasshi"},{"issue":"Suppl D","key":"10.1016\/j.rmed.2025.108168_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jac\/18.Supplement_D.133","article-title":"Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin","volume":"18","author":"Gleadhill","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9343(88)80336-X","article-title":"Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin","volume":"85","author":"Peterson","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.rmed.2025.108168_bib29","first-page":"528","article-title":"Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections","volume":"96","author":"Khan","year":"1989","journal-title":"Chest (Am. Coll. Chest Physicians)"},{"key":"10.1016\/j.rmed.2025.108168_bib30","first-page":"1913","article-title":"[Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin], Schweiz Med","volume":"119","author":"Chuard","year":"1989","journal-title":"Woche"},{"issue":"Suppl B","key":"10.1016\/j.rmed.2025.108168_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jac\/26.suppl_B.111","article-title":"Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections","volume":"26","author":"Vanderdonckt","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1532-5415.1991.tb04044.x","article-title":"A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections","volume":"39","author":"Hirata-Dulas","year":"1991","journal-title":"J. Am. Geriatr. Soc."},{"issue":"Suppl C","key":"10.1016\/j.rmed.2025.108168_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/28.suppl_C.81","article-title":"The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia","volume":"28","author":"Vogel","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.36.4.833","article-title":"Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia","volume":"36","author":"Carbon","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib36","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108168_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF01700406","article-title":"Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia","volume":"16","author":"Genn\u00e9","year":"1997","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00044011-199714050-00001","article-title":"Efficacy and tolerability of a teicoplanin-ciprofloxacin combination in severe community-acquired pneumonia","volume":"14","author":"Rizzato","year":"1997","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.rmed.2025.108168_bib39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1086\/516366","article-title":"Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults","volume":"26","author":"Aubier","year":"1998","journal-title":"Sparfloxacin European Study Group, Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00365549850160710","article-title":"A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia","volume":"30","author":"Norrby","year":"1998","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF01691581","article-title":"Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia","volume":"17","author":"Tr\u00e9moli\u00e8res","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0025-7753(00)71625-3","article-title":"[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin\/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]","volume":"115","author":"Kalbermatter","year":"2000","journal-title":"Med. Clin."},{"key":"10.1016\/j.rmed.2025.108168_bib43","first-page":"185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest (Am. Coll. Chest Physicians)"},{"key":"10.1016\/j.rmed.2025.108168_bib44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"L\u00e9ophonte","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108168_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.patbio.2005.07.010","article-title":"[Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]","volume":"53","author":"Tr\u00e9moli\u00e8res","year":"2005","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.rmed.2025.108168_bib46","first-page":"313","article-title":"[Observation of the therapeutic effects of gatifloxacin on community acquired pneumonia]","volume":"32","author":"Li","year":"2007","journal-title":"Chinese J. Antiobiotics"},{"key":"10.1016\/j.rmed.2025.108168_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2025.108168_bib48","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2025.108168_bib49","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib50","first-page":"32","article-title":"Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment","volume":"59","author":"Kohno","year":"2011","journal-title":"Jpn. J. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib51","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/AAC.05596-11","article-title":"Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies","volume":"56","author":"English","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib52","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib53","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.rmed.2025.108168_bib54","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3760\/cma.j.issn.0366-6999.20131635","article-title":"Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors","volume":"127","author":"Sun","year":"2014","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.rmed.2025.108168_bib55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.rmed.2025.108168_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jmii.2015.09.005","article-title":"A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia","volume":"50","author":"Liu","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.rmed.2025.108168_bib58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108168_bib59","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2025.108168_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.aprim.2017.08.003","article-title":"Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial","volume":"51","author":"Llor","year":"2019","journal-title":"Atenci\u00f3n Primaria"},{"key":"10.1016\/j.rmed.2025.108168_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","article-title":"Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial","volume":"52","author":"Yuan","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.rmed.2025.108168_bib62","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/03007995.2021.1885362","article-title":"A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia","volume":"37","author":"Li","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.rmed.2025.108168_bib63","article-title":"Etiology and efficacy of anti-microbial treatment for community-acquired pneumonia in adults requiring hospital admission in Ukraine","volume":"93","author":"Kaidashev","year":"2022","journal-title":"Acta Biomed."},{"key":"10.1016\/j.rmed.2025.108168_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107235","article-title":"A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients","volume":"64","author":"Li","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl A","key":"10.1016\/j.rmed.2025.108168_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/34.suppl_A.85","article-title":"Pneumonia in the elderly","volume":"34","author":"Woodhead","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2025.108168_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000238970","article-title":"In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens","volume":"39","author":"Malmborg","year":"1993","journal-title":"Chemotherapy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:16:16Z","timestamp":1762337776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"alternative-id":["S0954611125002306"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108168","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108168"}}